14678-86-5

Usage

Uses

Used in Pharmaceutical Research:
5-Amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester is utilized as a building block for the synthesis of various biologically active molecules, playing a crucial role in drug discovery and development. Its application in this field is driven by its potential to contribute to the treatment of a range of diseases and medical conditions.
Used in Drug Discovery and Development:
In the pharmaceutical industry, 5-Amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester is employed as a key component in the creation of new drugs. Its unique structure allows it to be a valuable asset in the development of therapeutic agents that target specific biological pathways or receptors.
Used in the Study of Structure-Activity Relationships:
5-Amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester also serves as a valuable tool in the study of the structure-activity relationships of related compounds. Understanding these relationships is essential for optimizing the potency, selectivity, and safety of new drug candidates, making 5-Amino-1-(2-chlorophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester instrumental in advancing pharmaceutical science.

Upstream product

• 41052-75-9 o-chlorophenylhydrazine hydrochloride 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 10449-07-7 (2-chlorophenyl)hydrazine 

Downstream Products

• 1345714-06-8 C₂₂H₂₅ClN₄O₃S 

Relevant academic research and scientific papers

Targeting Pim Kinases and DAPK3 to Control Hypertension

Sustained vascular smooth muscle hypercontractility promotes hypertension and cardiovascular disease. The etiology of hypercontractility is not completely understood. New therapeutic targets remain vitally important for drug discovery. Here we report that Pim kinases, in combination with DAPK3, regulate contractility and control hypertension. Using a co-crystal structure of lead molecule (HS38) in complex with DAPK3, a dual Pim/DAPK3 inhibitor (HS56) and selective DAPK3 inhibitors (HS94 and HS148) were developed to provide mechanistic insight into the polypharmacology of hypertension. In vitro and ex vivo studies indicated that Pim kinases directly phosphorylate smooth muscle targets and that Pim/DAPK3 inhibition, unlike selective DAPK3 inhibition, significantly reduces contractility. In vivo, HS56 decreased blood pressure in spontaneously hypertensive mice in a dose-dependent manner without affecting heart rate. These findings suggest including Pim kinase inhibition within a multi-target engagement strategy for hypertension management. HS56 represents a significant step in the development of molecularly targeted antihypertensive medications. Carlson et al. use crystal structure-guided medicinal chemistry techniques to develop a dual Pim/DAPK3 inhibitor (HS56) that reduces myosin phosphorylation and contractility in smooth muscle. Their findings reveal the contribution of Pim kinases to the pathology of hypertension, suggesting a novel multi-target engagement strategy for molecularly targeted antihypertensive medications.

Synthesis of 3H-pyrazolo[3,4-c]isoquinolines and thieno[3,2-c]isoquinolines via cascade imination/intramolecular decarboxylative coupling

A general approach for the synthesis of 3H-pyrazolo[3,4-c]isoquinolines and thieno[3,2-c]isoquinolines is described involving the implementation of a cascade imination/intramolecular decarboxylative coupling between potassium 2-amino(hetero)benzoates and 2-haloarylaldehydes. The reactions of pyrazole-based substrates require a Pd-Cu bimetallic system for superior yields whereas the thienyl-based substrates afford the products in excellent yields with a Pd-catalyst only.